Trial Identifiers
Use the hyperlinks, where available to access additional clinical trial information.
Trial sponsor
Janssen-Cilag Pty Ltd
Scientific Title
A Randomized Phase 2/3 Study of DACOGEN® (Decitabine) Plus JNJ-56022473 (Anti CD123) Versus DACOGEN (Decitabine) Alone in Patients With AML Who Are Not Candidates for Intensive Chemotherapy